Shijiazhuang No. 4 Pharmaceutical Co., Ltd. gets 6 Drug Registration Certificate

Recently  Shijiazhuang No. 4 Pharmaceutical Co., Ltd. gets 6 Drug Registration Certificate including Peritoneal Dialysis Solution (low calcium, lactic acid-Glucose 1.5%) , Peritoneal Dialysis Solution (low calcium, lactic acid-Glucose 2.5%), Peritoneal Dialysis Solution (low calcium, lactic acid-Glucose 4.25%), Peritoneal Dialysis Solution lactic acid-Glucose 1.5%) , Peritoneal Dialysis Solution (lactic acid-Glucose 2.5%), Peritoneal Dialysis Solution lactic acid-Glucose 4.25%).

Peritoneal dialysis is to use the peritoneum as the dialysis membrane and inject dialysate into the peritoneal cavity. The blood in the peritoneal capillary cavity can be exchanged with the dialysate. Metabolic wastes and excess water stored in the body are discharged with waste dialysate, and necessary substances are supplemented by osmotic fluid. By repeatedly infusing fresh dialysate into the abdominal cavity, the treatment objectives of toxin removal, dehydration, acidosis correction and electrolyte disturbance can be achieved.

With the development of peritoneal dialysis treatment,  today it has become an important part of renal replacement therapy together with hemodialysis and kidney transplantation due to its simple and convenient operation and exact curative effect. Compared with developed countries, the utilization rate of peritoneal dialysis treatment in China is relatively low and has a large market development space.